{"entity":{"id":"nct04468061","kind":"trial","name":"Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC","aka":[],"tldr":"A phase 2 trial of sacituzumab govitecan and pembrolizumab in triple-negative breast cancer, run by Dana-Farber Cancer Institute, now recruiting.","summary":"Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC is a phase 2, randomised interventional study registered as NCT04468061 by Dana-Farber Cancer Institute, with a registry enrolment figure of 110 participants, started 2020-07-20 and due to reach its primary completion in 2027-04-01. Interventions recorded: Sacituzumab Govitecan; Pembrolizumab. Conditions listed: Breast Cancer; Triple Negative Breast Cancer; PD-L1 Negative. Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04468061","url":"https://clinicaltrials.gov/study/NCT04468061"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["adc","checkpoint-inhibitor"],"targets":[],"drugs":["sacituzumab-govitecan","pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04468061","phase":"2","setting":"Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic Triple Negative Breast Cancer (TNBC)","sponsor":"Dana-Farber Cancer Institute","enrolled":110,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04468061/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}